REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Amid a solid earnings picture for the second quarter, many US-listed companies are beating their estimates. Combining the ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...